Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Ann. hepatol ; Ann. hepatol;16(2): 188-197, Mar.-Apr. 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-887222

RESUMO

ABSTRACT Background and aim. The combination of Sofosbuvir (SOF) and Ledipasvir (LDV) has been lead to considerable enhancement of treatment of hepatitis C virus (HCV) genotype 1 infection. A meta-analysis of the currently available studies was undertaken with the aim to evaluate the antiviral efficacy of SOF/LDV therapy for 12 or 24 weeks with or without Ribavirin (RBV) in patients with HCV genotype 1 infection. Material and methods. In this meta-analysis, we searched databases including PubMed, Scopus, Science Direct and Web of Science using appropriate keywords. All papers which evaluated the efficacy of combination therapy of SOF/LDV with or without RBV for 12 or 24 weeks among patients with HCV genotype 1 infection were included. Results. The 20 published articles were assessed for eligibility and finally 10 articles pooling 2248 participants were included in this meta-analysis. Pooled SVR12 for four SOF/LDV regimens were 95% (95%CI = 93%-97%) for 12 weeks of treatment with SOF/LDV, 97% (95%CI = 95%-98%) for 24 weeks of treatment with SOF/LDV, 96% (95%CI = 94%-97%) for 12 weeks of treatment with SOF/ LDV/RBV and 98% (95%CI = 97%-99%) for 24 weeks of treatment with SOF/LDV/RBV. Only in treatment regimen of SOF/LDV for 12 weeks, cirrhosis had a significant effect on the SVR12 (OR = 0.21, 95%CI = 0.07-0.66). Furthermore, NS5A resistance-associated substitutions at baseline were associated with decrease in the rate of SVR (OR = 0.31, 95%CI = 0.2-0.5). Conclusions. The Interferon-free regimen of SOF/LDV for 12 or 24 weeks with or without RBV is highly effective for treatment of patients with HCV genotype 1 infection.


Assuntos
Humanos , Antivirais/uso terapêutico , Benzimidazóis/uso terapêutico , Hepatite C/tratamento farmacológico , Hepacivirus/efeitos dos fármacos , Fluorenos/uso terapêutico , Sofosbuvir/uso terapêutico , Antivirais/efeitos adversos , Ribavirina/uso terapêutico , Fatores de Tempo , Benzimidazóis/efeitos adversos , Distribuição de Qui-Quadrado , Razão de Chances , Resultado do Tratamento , Hepatite C/diagnóstico , Hepatite C/virologia , Hepacivirus/genética , Quimioterapia Combinada , Fluorenos/efeitos adversos , Sofosbuvir/efeitos adversos , Resposta Viral Sustentada , Genótipo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA